Inogen (INGN) Sets New 1-Year High at $194.23

Inogen Inc (NASDAQ:INGN)’s share price hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $194.23 and last traded at $189.73, with a volume of 1988 shares. The stock had previously closed at $193.20.

Several equities analysts recently issued reports on the company. KeyCorp assumed coverage on Inogen in a report on Wednesday, June 6th. They set an “equal weight” rating for the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Inogen in a report on Wednesday, June 13th. ValuEngine raised Inogen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. JPMorgan Chase & Co. lifted their price objective on Inogen from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Tuesday, May 1st. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $170.00 price objective (up from $150.00) on shares of Inogen in a report on Tuesday, May 1st. Two analysts have rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $178.00.

The stock has a market capitalization of $3.99 billion, a price-to-earnings ratio of 142.03, a price-to-earnings-growth ratio of 4.74 and a beta of 1.10.



Inogen (NASDAQ:INGN) last released its quarterly earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.19. The company had revenue of $79.05 million during the quarter, compared to the consensus estimate of $63.86 million. Inogen had a return on equity of 14.81% and a net margin of 9.36%. Inogen’s revenue was up 50.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.27 earnings per share. equities analysts predict that Inogen Inc will post 1.77 EPS for the current year.

In other Inogen news, CFO Alison Bauerlein sold 5,000 shares of the firm’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $180.69, for a total transaction of $903,450.00. Following the completion of the transaction, the chief financial officer now owns 9,161 shares of the company’s stock, valued at $1,655,301.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Byron Myers sold 8,056 shares of the firm’s stock in a transaction on Wednesday, June 20th. The stock was sold at an average price of $190.58, for a total value of $1,535,312.48. Following the transaction, the executive vice president now directly owns 45,331 shares of the company’s stock, valued at approximately $8,639,181.98. The disclosure for this sale can be found here. Insiders have sold 58,589 shares of company stock valued at $10,581,530 in the last three months. 5.29% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Inogen by 4.8% during the first quarter. BlackRock Inc. now owns 2,418,048 shares of the medical technology company’s stock worth $297,032,000 after buying an additional 111,514 shares in the last quarter. Brown Capital Management LLC grew its position in shares of Inogen by 1.8% in the fourth quarter. Brown Capital Management LLC now owns 2,260,706 shares of the medical technology company’s stock valued at $269,205,000 after purchasing an additional 40,994 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Inogen in the first quarter valued at $36,612,000. Wells Fargo & Company MN grew its position in shares of Inogen by 7.9% in the first quarter. Wells Fargo & Company MN now owns 297,745 shares of the medical technology company’s stock valued at $36,575,000 after purchasing an additional 21,714 shares during the period. Finally, Fred Alger Management Inc. grew its position in shares of Inogen by 7.9% in the fourth quarter. Fred Alger Management Inc. now owns 248,232 shares of the medical technology company’s stock valued at $29,559,000 after purchasing an additional 18,269 shares during the period. 97.86% of the stock is owned by institutional investors.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply